Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' reply.
Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH.
Weller M, et al. Among authors: recht ld.
Lancet Oncol. 2017 Dec;18(12):e709-e710. doi: 10.1016/S1470-2045(17)30856-2.
Lancet Oncol. 2017.
PMID: 29208433
No abstract available.